Vaccine maker BioNTech reports potential multiple sclerosis breakthrough


BioNTech, the German biotechnology company that paired with Pfizer to develop the first COVID-19 vaccine approved in the U.S., reports in the journal Science that a new vaccine using the same mRNA technique has proved effective in treating or stopping multiple sclerosis in lab mice. MS is caused not by a virus but by the immune system malfunctioning and attacking the protective covering of nerve cells in the brain and spinal cord, disrupting signals between those cells and their targets in the body, causing neurological, sensory, and motor issues.
BioNTech said it successfully encoded MS-specific autoantigens that, when delivered via its experimental vaccine, stopped MS symptoms in mice bred with a condition mirroring MS in humans, and prevented further deterioration in mice with early signs of MS. Mice given a placebo showed typical MS symptoms.
Existing MS treatments "work by systemically suppressing the immune system," Angus Liu writes in Fierce Biotech. "That can control MS, but it also leaves patients vulnerable to infections." BioNTech's vaccine did not compromise normal immune function. The researchers said their findings suggest that mRNA vaccines, which can be developed quickly, could soon be used to treat "disease-causing antigens of individual patients."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Does depopulation threaten humanity?
Talking Points Falling birth rates could create a 'smaller, sadder, poorer future'
-
New White House guidance means federal employees could be hearing more religious talk at work
The Explainer Employees can now try to persuade coworkers of why their religion is 'correct'
-
Real-life couples creating real-deal sparks in the best movies to star IRL partners
The Week Recommends The chemistry between off-screen items can work wonders
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
-
Crypto firm Coinbase hacked, faces SEC scrutiny
Speed Read The Securities and Exchange Commission has also been investigating whether Coinbase misstated its user numbers in past disclosures
-
Starbucks baristas strike over dress code
speed read The new uniform 'puts the burden on baristas' to buy new clothes, said a Starbucks Workers United union delegate
-
Warren Buffet announces surprise retirement
speed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement